Abstract 1379P
Background
C-MET alterations implicated as a negative prognostic factor. It can occur as exon 14 (METex14) skipping mutations, gene amplification, and protein overexpression. Vebreltinib (PLB-1001) is a potent highly selective c-MET inhibitor, which has shown promising results in pts with NGS-identified advanced METex14 skipping NSCLC in our previous phase I study. Here we present data from pts with METex14 mutation (Cohort 1) from a phase II, open-label, multicenter and multi-cohort KUNPENG study of PLB1001 conducted in locally advanced or metastatic NSCLC pts with c-MET alterations.
Methods
Eligible pts were ≥18 years of age, ECOG PS 0∼1 with stage IIIB/IV NSCLC. Pts in Cohort 1 received 200 mg of Vebreltinib twice daily (28 days as a cycle) until disease progression, death, AE leading to discontinuation or withdrawal of consent. The primary endpoint was objective response rate (ORR) assessed by blinded independent review committee (BIRC) per RECIST v1.1. Secondary endpoints included investigator-assessed (INV) ORR, disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS) and overall survival (OS).
Results
As of 09-Aug-2022, 113 pts were enrolled, among whom 52 pts were in Cohort 1. 32.7% (17/52) pts previously received systematic therapy for advanced or metastatic NSCLC. The primary endpoint ORR was 75% (95% CI: 61.1%∼86.0%) per BIRC, while the ORR was 77.1% (95% CI: 59.9%∼89.6%) in treatment-naïve pts and 70.6% (95% CI: 44.0%∼89.7%) in previously-treated pts. ORR per INV was 69.2% (95% CI: 54.9%∼81.3%), while the ORR was 74.3% (95% CI: 56.7%∼87.5%) in treatment-naïve pts and 58.8% (95% CI: 32.9%∼81.6%) in previously-treated pts. Per BIRC, DCR was 96.2%, median DoR was 15.9 months, median TTR was 1.0 month, median PFS was 14.1 months and median OS was 20.7 months. Among pts with baseline brain metastases (N=5), ORR was 100.0%. The most common (≥20%) TRAEs in all the 113 pts were peripheral edema (56.6%), hypoalbuminemia (22.1%) and hypoproteinemia (19.5%). Most of the TRAEs were grade 1/2.
Conclusions
Vebreltinib showed promising efficacy and favorable safety in patients with METex14 mutant NSCLC.
Clinical trial identification
NCT04258033.
Editorial acknowledgement
Legal entity responsible for the study
Beijing Pearl Biotechnology Co., Ltd. Avistone Biotechnology Limited.
Funding
Beijing Pearl Biotechnology Co., Ltd. Avistone Biotechnology Limited.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20